Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis

Etienne Crickx; Sebastian Wittnebel; Florence Pasquier; Alina Danu; Jean Henri Bourhis; Vincent Ribrag; Francois Boué; Corinne Miceli; Xavier Mariette; Philippe Moreau; Stéphane De Botton; David Ghez

doi:10.1016/j.ejca.2012.08.009

Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis

Etienne Crickx, Sebastian Wittnebel, Florence Pasquier, Alina Danu, Jean Henri Bourhis, Vincent Ribrag, Francois Boué, Corinne Miceli, Xavier Mariette, Philippe Moreau, Stéphane De Botton, David Ghez

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

We describe the striking and unexpected evolution of 10 patients with de novo multiple myeloma treated with novel-agent based induction therapy, who displayed a dissociated evolution characterised by an apparent good response contrasting with the concomitant development of aggressive non-secreting plasmocytomas immediately before, or just after, autologous stem cell transplantation. Patients did not respond to salvage therapies. Eight of them died from progression less than 12 months after diagnosis. This unusual evolution in the era of novel agents warrants further scrutiny.

langue originale	Anglais
Pages (de - à)	411-415
Nombre de pages	5
journal	European Journal of Cancer
Volume	49
Numéro de publication	2
Les DOIs	https://doi.org/10.1016/j.ejca.2012.08.009
état	Publié - 1 janv. 2013

Accès au document

10.1016/j.ejca.2012.08.009

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Crickx, E., Wittnebel, S., Pasquier, F., Danu, A., Bourhis, J. H., Ribrag, V., Boué, F., Miceli, C., Mariette, X., Moreau, P., Botton, S. D., & Ghez, D. (2013). Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis. European Journal of Cancer, 49(2), 411-415. https://doi.org/10.1016/j.ejca.2012.08.009

@article{8d79c612f6ca4273b60b68d82d2323ae,

title = "Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis",

abstract = "We describe the striking and unexpected evolution of 10 patients with de novo multiple myeloma treated with novel-agent based induction therapy, who displayed a dissociated evolution characterised by an apparent good response contrasting with the concomitant development of aggressive non-secreting plasmocytomas immediately before, or just after, autologous stem cell transplantation. Patients did not respond to salvage therapies. Eight of them died from progression less than 12 months after diagnosis. This unusual evolution in the era of novel agents warrants further scrutiny.",

keywords = "Myeloma, Prognosis, Treatment",

author = "Etienne Crickx and Sebastian Wittnebel and Florence Pasquier and Alina Danu and Bourhis, {Jean Henri} and Vincent Ribrag and Francois Bou{\'e} and Corinne Miceli and Xavier Mariette and Philippe Moreau and Botton, {St{\'e}phane De} and David Ghez",

year = "2013",

month = jan,

day = "1",

doi = "10.1016/j.ejca.2012.08.009",

language = "English",

volume = "49",

pages = "411--415",

journal = "European Journal of Cancer",

issn = "0959-8049",

number = "2",

}

Crickx, E, Wittnebel, S, Pasquier, F, Danu, A, Bourhis, JH, Ribrag, V, Boué, F, Miceli, C, Mariette, X, Moreau, P, Botton, SD & Ghez, D 2013, 'Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis', European Journal of Cancer, VOL. 49, Numéro 2, p. 411-415. https://doi.org/10.1016/j.ejca.2012.08.009

TY - JOUR

T1 - Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis

AU - Crickx, Etienne

AU - Wittnebel, Sebastian

AU - Pasquier, Florence

AU - Danu, Alina

AU - Bourhis, Jean Henri

AU - Ribrag, Vincent

AU - Boué, Francois

AU - Miceli, Corinne

AU - Mariette, Xavier

AU - Moreau, Philippe

AU - Botton, Stéphane De

AU - Ghez, David

PY - 2013/1/1

Y1 - 2013/1/1

N2 - We describe the striking and unexpected evolution of 10 patients with de novo multiple myeloma treated with novel-agent based induction therapy, who displayed a dissociated evolution characterised by an apparent good response contrasting with the concomitant development of aggressive non-secreting plasmocytomas immediately before, or just after, autologous stem cell transplantation. Patients did not respond to salvage therapies. Eight of them died from progression less than 12 months after diagnosis. This unusual evolution in the era of novel agents warrants further scrutiny.

AB - We describe the striking and unexpected evolution of 10 patients with de novo multiple myeloma treated with novel-agent based induction therapy, who displayed a dissociated evolution characterised by an apparent good response contrasting with the concomitant development of aggressive non-secreting plasmocytomas immediately before, or just after, autologous stem cell transplantation. Patients did not respond to salvage therapies. Eight of them died from progression less than 12 months after diagnosis. This unusual evolution in the era of novel agents warrants further scrutiny.

KW - Myeloma

KW - Prognosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84872102686&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2012.08.009

DO - 10.1016/j.ejca.2012.08.009

M3 - Article

C2 - 22980726

AN - SCOPUS:84872102686

SN - 0959-8049

VL - 49

SP - 411

EP - 415

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 2

ER -